Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Soo Young | - |
dc.contributor.author | Choi, Minhye | - |
dc.contributor.author | Ban, Hyo-Jeong | - |
dc.contributor.author | Lee, Chang Hyeon | - |
dc.contributor.author | Park, Soojun | - |
dc.contributor.author | Kim, HanKyeom | - |
dc.contributor.author | Kim, Young-Sik | - |
dc.contributor.author | Lee, Young Seek | - |
dc.contributor.author | Lee, Ji-Yun | - |
dc.date.accessioned | 2021-09-03T10:41:09Z | - |
dc.date.available | 2021-09-03T10:41:09Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01-31 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84860 | - |
dc.description.abstract | Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX, ERBB4, and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.subject | SIGNALING ACTIVATION PATTERNS | - |
dc.subject | MTOR PATHWAY | - |
dc.subject | PI3K/AKT/MTOR PATHWAY | - |
dc.subject | PROGNOSTIC-FACTORS | - |
dc.subject | SOMATIC MUTATIONS | - |
dc.subject | MAMMALIAN TARGET | - |
dc.subject | UTERINE CERVIX | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | LUNG-CANCER | - |
dc.subject | ERBB4 | - |
dc.title | Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, HanKyeom | - |
dc.contributor.affiliatedAuthor | Kim, Young-Sik | - |
dc.contributor.affiliatedAuthor | Lee, Ji-Yun | - |
dc.identifier.doi | 10.18632/oncotarget.14098 | - |
dc.identifier.scopusid | 2-s2.0-85018911358 | - |
dc.identifier.wosid | 000393295500078 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.5, pp.8095 - 8104 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 8095 | - |
dc.citation.endPage | 8104 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | SIGNALING ACTIVATION PATTERNS | - |
dc.subject.keywordPlus | MTOR PATHWAY | - |
dc.subject.keywordPlus | PI3K/AKT/MTOR PATHWAY | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | SOMATIC MUTATIONS | - |
dc.subject.keywordPlus | MAMMALIAN TARGET | - |
dc.subject.keywordPlus | UTERINE CERVIX | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | ERBB4 | - |
dc.subject.keywordAuthor | cervical small cell neuroendocrine tumor | - |
dc.subject.keywordAuthor | ATRX | - |
dc.subject.keywordAuthor | ERBB4 | - |
dc.subject.keywordAuthor | AKT/mTOR | - |
dc.subject.keywordAuthor | whole exome sequencing | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.